The incidence of allergic diseases has dramatically increased in the last decades. The dysregulation of our immune systems ...
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial ...
The study is testing GLK-321, an eye drop drug, in several dose levels. It aims to lower signs and symptoms of Demodex blepharitis and could become a new product in Glaukos’ growing eye care pipeline ...
Preoperative identification and eradication of Demodex can improve ocular-surface comfort and may mitigate cataract-surgery ...
As of Thursday, April 16, Tarsus Pharmaceuticals, Inc.’s TARS share price has dipped by 5.07%, which has investors questioning if this is right time to buy.
20d
Eye Doctors Share 6 Health Concerns They Can Spot In Your Eye Before You Realise Anything Is Wrong
Along those lines, you might be surprised to hear that symptoms of certain health problems can be spotted in your eye, of all ...
IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory ...
Tarsus Pharmaceuticals Inc. delivered higher-than-expected fourth quarter revenue driven by surging demand for its eyedrop Xdemvy. More than two years into commercial launch, sales of Xdemvy, the ...
Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results